News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
740,821 Results
Type
Article (45045)
Company Profile (460)
Press Release (695316)
Section
Business (217177)
Career Advice (2236)
Deals (37871)
Drug Delivery (108)
Drug Development (84963)
Employer Resources (175)
FDA (16756)
Job Trends (15518)
News (365804)
Policy (34298)
Tag
2024 BioCapital Digital (11)
2024 BioForest Digital (2)
2024 BioForest Standard (1)
2024 BioMidwest Digital (10)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (8)
2024 Bio NC Standard (2)
2024 Biotech Bay Standard (18)
2024 Biotech Beach Digital (10)
2024 Biotech Beach Standard (5)
2024 Genetown Digital (8)
2024 Genetown Standard (10)
2024 Lone Star Bio Digital (8)
2024 Pharm Country Digital (8)
2024 Pharm Country Standard (6)
2025 BioForest Digital (4)
2025 Lone Star Bio Digital (8)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (2)
2026 Biotech Bay Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (2)
2026 Genetown Elite (3)
2026 Pharm Country Elite (1)
2026 Pharm Country Standard (1)
Academia (2701)
Accelerated approval (5)
Adcomms (25)
Allergies (83)
Alliances (52597)
ALS (89)
Alzheimer's disease (1419)
Antibody-drug conjugate (ADC) (127)
Approvals (16740)
Artificial intelligence (275)
Autoimmune disease (20)
Automation (14)
Bankruptcy (387)
Best Places to Work (11994)
BIOSECURE Act (18)
Biosimilars (105)
Biotechnology (346)
Bladder cancer (63)
Brain cancer (27)
Breast cancer (264)
Cancer (2094)
Cardiovascular disease (175)
Career advice (1872)
Career pathing (31)
CAR-T (149)
Cell therapy (434)
Cervical cancer (19)
Clinical research (68688)
Collaboration (822)
Compensation (473)
Complete response letters (24)
COVID-19 (2680)
CRISPR (40)
C-suite (227)
Cystic fibrosis (104)
Data (2024)
Decentralized trials (2)
Denatured (26)
Depression (46)
Diabetes (258)
Diagnostics (6553)
Digital health (19)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (134)
Drug pricing (109)
Drug shortages (27)
Duchenne muscular dystrophy (92)
Earnings (91791)
Editorial (36)
Employer branding (22)
Employer resources (150)
Events (120377)
Executive appointments (678)
FDA (17914)
Featured Employer (55)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (733)
Gene editing (107)
Generative AI (23)
Gene therapy (311)
GLP-1 (752)
Government (4556)
Grass and pollen (4)
Guidances (49)
Healthcare (19577)
Huntington's disease (23)
IgA nephropathy (27)
Immunology and inflammation (118)
Indications (27)
Infectious disease (2816)
Inflammatory bowel disease (141)
Inflation Reduction Act (11)
Influenza (50)
Intellectual property (89)
Interviews (350)
IPO (17153)
IRA (44)
Job creations (3981)
Job search strategy (1593)
Kidney cancer (9)
Labor market (34)
Layoffs (498)
Leadership (19)
Legal (8474)
Liver cancer (72)
Lung cancer (300)
Lymphoma (136)
Machine learning (4)
Management (60)
Manufacturing (290)
MASH (65)
Medical device (13851)
Medtech (13856)
Mergers & acquisitions (21198)
Metabolic disorders (681)
Multiple sclerosis (75)
NASH (20)
Neurodegenerative disease (94)
Neuropsychiatric disorders (30)
Neuroscience (1945)
NextGen: Class of 2025 (6978)
Non-profit (4640)
Northern California (2506)
Now hiring (37)
Obesity (371)
Opinion (235)
Ovarian cancer (74)
Pain (82)
Pancreatic cancer (77)
Parkinson's disease (145)
Partnered (20)
Patents (210)
Patient recruitment (98)
Peanut (48)
People (60394)
Pharmaceutical (91)
Pharmacy benefit managers (20)
Phase I (21508)
Phase II (30182)
Phase III (22502)
Pipeline (1084)
Podcasts (75)
Policy (123)
Postmarket research (2716)
Preclinical (9193)
Press Release (70)
Prostate cancer (98)
Psychedelics (37)
Radiopharmaceuticals (263)
Rare diseases (389)
Real estate (6296)
Recruiting (66)
Regulatory (23310)
Reports (47)
Research institute (2458)
Resumes & cover letters (379)
Rett syndrome (4)
RNA editing (4)
RSV (40)
Schizophrenia (73)
Series A (130)
Series B (84)
Service/supplier (12)
Sickle cell disease (56)
Southern California (2171)
Special edition (18)
Spinal muscular atrophy (153)
Sponsored (29)
Startups (3864)
State (2)
Stomach cancer (14)
Supply chain (62)
Tariffs (11)
The Weekly (47)
United States (22206)
Vaccines (688)
Venture capitalists (39)
Webinars (13)
Weight loss (255)
Women's health (35)
Worklife (16)
Date
Today (12)
Last 7 days (681)
Last 30 days (2566)
Last 365 days (35160)
2025 (8863)
2024 (36959)
2023 (41488)
2022 (52844)
2021 (57464)
2020 (55763)
2019 (48489)
2018 (36634)
2017 (33860)
2016 (33573)
2015 (39735)
2014 (33928)
2013 (28917)
2012 (31034)
2011 (31753)
2010 (30170)
Location
Africa (803)
Alabama (54)
Alaska (7)
Arizona (240)
Arkansas (14)
Asia (40815)
Australia (6763)
California (5771)
Canada (1898)
China (490)
Colorado (257)
Connecticut (273)
Delaware (133)
Europe (89751)
Florida (837)
Georgia (196)
Idaho (61)
Illinois (530)
India (25)
Indiana (299)
Iowa (10)
Japan (146)
Kansas (104)
Kentucky (26)
Louisiana (10)
Maine (69)
Maryland (861)
Massachusetts (4452)
Michigan (231)
Minnesota (389)
Mississippi (2)
Missouri (81)
Montana (30)
Nebraska (25)
Nevada (56)
New Hampshire (68)
New Jersey (1638)
New Mexico (31)
New York (1642)
North Carolina (1004)
North Dakota (8)
Northern California (2506)
Ohio (198)
Oklahoma (14)
Oregon (38)
Pennsylvania (1283)
Puerto Rico (9)
Rhode Island (29)
South America (1197)
South Carolina (18)
South Dakota (1)
Southern California (2171)
Tennessee (97)
Texas (857)
Utah (170)
Virginia (137)
Washington D.C. (61)
Washington State (541)
West Virginia (3)
Wisconsin (53)
740,821 Results for "curagen corporation acquired by celldex therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Celldex Therapeutics to Present at Upcoming March 2025 Investor Conferences
March 5, 2025
·
1 min read
Press Releases
Celldex Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update
February 27, 2025
·
12 min read
Pharm Country
Celldex Therapeutics to Present at Jefferies 2024 Healthcare Conference
Celldex Therapeutics, Inc. announced that management will participate in a fireside chat at the Jefferies Healthcare Conference on Thursday, June 6th at 10:00 am ET.
June 4, 2024
·
1 min read
Business
Celldex Reports First Quarter 2024 Financial Results and Provides Corporate Update
Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the first quarter ended March 31, 2024 and provided a corporate update.
May 6, 2024
·
11 min read
Press Releases
Celldex Therapeutics Presents Positive Preclinical Data from Inflammatory Bispecific Antibody Program CDX-622 at AAAAI 2025
March 3, 2025
·
5 min read
Press Releases
Celldex Therapeutics to Present at Upcoming Investor Conferences
November 12, 2024
·
1 min read
Press Releases
Celldex Therapeutics Presents Positive Results from Barzolvolimab Phase 2 Studies in Patients with Chronic Urticaria Demonstrating Improved Disease Control and Quality of Life at AAAAI 2025
March 3, 2025
·
9 min read
Business
Celldex Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update
Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the fourth quarter and year ended December 31, 2023 and provided a corporate update.
February 26, 2024
·
13 min read
Drug Development
Celldex Therapeutics Presents Data Demonstrating Profound Improvements in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2024
Celldex Therapeutics, Inc. announced data demonstrating that barzolvolimab profoundly improves angioedema at 12 weeks in the Company’s Phase 2 clinical trial in chronic spontaneous urticaria.
June 2, 2024
·
8 min read
Pharm Country
Celldex Therapeutics Announces Pricing of Upsized $400 Million Public Offering of Common Stock
Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced the pricing of an upsized underwritten public offering of 8,520,000 shares of its common stock at a public offering price of $47.00 per share. All of the shares to be sold in the offering are to be sold by Celldex.
February 29, 2024
·
4 min read
1 of 74,083
Next
